A new Cancer therapy in an early-stage trial by the U.S. National Cancer Institute "continued to be safe and show durable responses against solid tumors for some patients," reports Bloomberg. "In a trial of 14 patients who received different doses, three patients' cancers have shrunk partially, according to a study presented Sunday... The researchers had presented initial positive data in November, and the updated study shows that the three partial responses were durable, with one cervical cancer patient's response continuing at 15 months." Kite Pharma Inc. licensed the therapy, and by the end of the year will file an "investigational new drug" application with the FDA to begin the next round of testing. The therapy involves genetically engineered T cells, targeted to the solid tumors using the MAGE-A3 protein as a unique marker expressed in up to 30 percent of cancers.

Read more of this story at Slashdot.